Patients diagnosed with cancer after skipping appointment more likely to die within a year

September 12, 2019

Cancer patients who miss an urgent referral appointment for their symptoms are 12% more likely to die within 12 months of diagnosis, a major new study has found.

The study, funded by Yorkshire Cancer Research, showed that male patients and those under 30 or over 85 years of age are more likely to skip their appointment, as are people who live in disadvantaged neighbourhoods and people who have been referred due to gastrointestinal problems.

The authors of the study say that more support is needed for patients at risk of non-attendance.

Led by researchers at the University of York and Hull York Medical School, the study looked at data from more than 100,000 patients who had been urgently referred by around 100 different GP practices in the North of England.

The majority of patients in the study (95%) attended their referral appointment, but a significant minority (5% or 5,673 people) did not.

While the study found that only one in 18 of the patients who skipped their appointment went on to be diagnosed with cancer - compared to one in 10 of those who did attend - the outlook for patients who missed their appointment and did have cancer was significantly worse.

The study revealed that 34.6% of non-attending patients with cancer had an advanced stage of the disease at diagnosis compared to 18.4% of attenders with cancer.

Having a more advanced stage of the disease is likely to be a reason why more non-attending patients with cancer died within a year of diagnosis (31.3% compared to 19.2% of attenders), the researchers say.

Dr Peter Knapp, from the Department of Health Sciences at the University of York and Hull York Medical School, said: "Our study showed cancer diagnosis was less likely in non-attending patients but those who are diagnosed have worse outcomes than attending patients with cancer. This may be due to later presentation to their GP and more advanced disease at referral.

"Non-attendance at urgent referral appointments for suspected cancer involves a minority of patients, but happens in somewhat predictable groups. For example, we found that patients with suspected gastrointestinal cancer were among the least likely to attend - this may be due to concerns about unpleasant or embarrassing procedures.

"Our research suggests that more could be done to identify individuals at risk of non-attendance and offer extra support."

The NHS's 'Two Week Wait' policy aims to ensure that patients with suspected cancer are seen by a consultant within two weeks of an urgent GP referral.

While there is more awareness around the issues of ignored cancer screening invitations and the waste of resources incurred from missed GP appointments, the study is the first to focus on non-attendance of symptomatic patients referred due to suspected cancer.

Dr Stuart Griffiths, Director of Research and Services at Yorkshire Cancer Research, said: "Early diagnosis is vital in ensuring more people survive cancer, but there are many challenges facing both doctors and patients when it comes to accessing diagnosis and treatment swiftly. The charity is looking at ways it can work with the NHS and other research partners to determine how it can address factors leading to non-attendance at urgent referral appointments."
-end-
Patient non-attendance at urgent referral appointments for suspected cancer and its links to cancer diagnosis and one year mortality: a cohort study of patients referred on the Two Week Wait pathway is published in Cancer Epidemiology.

University of York

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.